Onyx has goods to draw interest from other big drug makers
This article was originally published in Scrip
Onyx Pharmaceuticals CEO Anthony Coles responded to an unsolicited bid from Amgen in a relatively short timeframe and with a bit of bravado, answering the big biotech company with a stern rejection and a swift plan to seek other potential buyers.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.